Singapore markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
12.10+0.33 (+2.80%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 51.23B
Enterprise value 31.14B
Trailing P/E N/A
Forward P/E 1-7.47
PEG Ratio (5 yr expected) 1-0.10
Price/sales (ttm)14.85
Price/book (mrq)7.70
Enterprise value/revenue 313.74
Enterprise value/EBITDA 7-5.10

Trading information

Stock price history

Beta (5Y monthly) 1.39
52-week change 3-20.18%
S&P500 52-week change 335.11%
52-week high 322.40
52-week low 310.10
50-day moving average 311.52
200-day moving average 314.49

Share statistics

Avg vol (3-month) 31.28M
Avg vol (10-day) 31.14M
Shares outstanding 5101.91M
Implied shares outstanding 6N/A
Float 79.82M
% held by insiders 10.14%
% held by institutions 1104.73%
Shares short (30 Aug 2021) 427.22M
Short ratio (30 Aug 2021) 420.14
Short % of float (30 Aug 2021) 430.56%
Short % of shares outstanding (30 Aug 2021) 426.71%
Shares short (prior month 29 Jul 2021) 425.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin -281.99%
Operating margin (ttm)-272.99%

Management effectiveness

Return on assets (ttm)-33.85%
Return on equity (ttm)-96.72%

Income statement

Revenue (ttm)83.03M
Revenue per share (ttm)0.89
Quarterly revenue growth (yoy)-1.00%
Gross profit (ttm)-120.88M
EBITDA -223.71M
Net income avi to common (ttm)-234.14M
Diluted EPS (ttm)-2.52
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)257.68M
Total cash per share (mrq)2.53
Total debt (mrq)165.16M
Total debt/equity (mrq)103.15
Current ratio (mrq)4.47
Book value per share (mrq)1.57

Cash flow statement

Operating cash flow (ttm)-199.54M
Levered free cash flow (ttm)-114.63M